Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell Lymphoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to evaluate the clinical features and the long-term outcomes of primary conjunctival marginal zone B-cell lymphoma (MZBCL) patients who were treated with radiation therapy (RT). Materials and Methods Retrospective data of 79 patients with 121 primary conjunctival MZBCL lesions were collected from January 1, 2001 till June 30, 2014. All lesions were treated by local RT (26 Gy) with patient-specific customized lens-shielding device. Results The current Korean patients’ cohort showed younger median age at diagnosis (38 years), great female preponderance (78.5%) and more frequent bilateral involvement (53.2%) than the previous studies. Following 26 Gy’s RT, excellent clinical outcomes were achieved: 5-year rates of overall survival, local relapse-free survival, and contralateral relapse-free survival were 100%, 98.1%, and 91.5%, respectively. Two patients (2.5%) developed local relapse and five (6.3%) developed relapse at initially uninvolved contralateral conjunctiva with median interval of 52.9 months, and late adverse events of grade 2 and 3 occurred in seven (8.8%) and two (2.5%) patients, respectively. Conclusion 26 Gy’s RT was highly effective and safe, with the use of lens-shielding device, in treating patients with primary conjunctival MZBCL.
Abstract
Purpose The purpose of this study was to evaluate the clinical features and the long-term outcomes of primary conjunctival marginal zone B-cell lymphoma (MZBCL) patients who were treated with radiation therapy (RT). Materials and Methods Retrospective data of 79 patients with 121 primary conjunctival MZBCL lesions were collected from January 1, 2001 till June 30, 2014. All lesions were treated by local RT (26 Gy) with patient-specific customized lens-shielding device. Results The current Korean patients’ cohort showed younger median age at diagnosis (38 years), great female preponderance (78.5%) and more frequent bilateral involvement (53.2%) than the previous studies. Following 26 Gy’s RT, excellent clinical outcomes were achieved: 5-year rates of overall survival, local relapse-free survival, and contralateral relapse-free survival were 100%, 98.1%, and 91.5%, respectively. Two patients (2.5%) developed local relapse and five (6.3%) developed relapse at initially uninvolved contralateral conjunctiva with median interval of 52.9 months, and late adverse events of grade 2 and 3 occurred in seven (8.8%) and two (2.5%) patients, respectively. Conclusion 26 Gy’s RT was highly effective and safe, with the use of lens-shielding device, in treating patients with primary conjunctival MZBCL.
참고문헌 (24)
- Kirkegaard MM, "Malignant lymphoma of the conjunctiva", Surv Ophthalmol, 60, pp.444~458 (2015)[DOI]
- Kirkegaard MM, "Conjunctival lymphoma: an international multicenter retrospective study", JAMA Ophthalmol, 134, pp.406~414 (2016)[DOI]
- Matsuo T, "Spontaneous regression of bilateral conjunctival extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue", J Clin Exp Hematop, 47, pp.79~81 (2007)[DOI]
- Tanimoto K, "Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma", Ann Oncol, 17, pp.135~140 (2006)[DOI]
- Han JJ, "Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma", Ann Hematol, 94, pp.575~581 (2015)[DOI]
- Ferreri AJ, "Chlamydophila psittaci eradication with doxycycline as firstline targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial", J Clin Oncol, 30, pp.2988~2994 (2012)[DOI]
- Ohga S, "Radiotherapy for early-stage primary ocular adnexal mucosa-associated lymphoid tissue lymphoma", Anticancer Res, 33, pp.5575~5578 (2013)
- Uno T, "Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients", Cancer, 98, pp.865~871 (2003)[DOI]
- Ferrufino-Ponce ZK, "Radiotherapy and cataract formation", Semin Ophthalmol, 21, pp.171~180 (2006)[DOI]
- Hashimoto N, "Long-term outcome and patterns of failure in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy", Int J Radiat Oncol Biol Phys, 82, pp.1509~1514 (2012)[DOI]
- Hoskin PJ, "4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial", Lancet Oncol, 15, pp.457~463 (2014)[DOI]
- Nam H, "Prognostic significance of anatomic subsites: results of radiation therapy for 66 patients with localized orbital marginal zone B cell lymphoma", Radiother Oncol, 90, pp.236~241 (2009)[DOI]
- Woolf DK, "Outcomes of primary lymphoma of the ocular adnexa (orbital lymphoma) treated with radiotherapy", Clin Oncol (R Coll Radiol), 27, pp.153~159 (2015)[DOI]
- Goda JS, "Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity", Int J Radiat Oncol Biol Phys, 81, pp.e659~e666 (2011)[DOI]
- Harada K, "Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes", Int J Radiat Oncol Biol Phys, 88, pp.650~654 (2014)[DOI]
- Parikh RR, "Long-term outcomes and patterns of failure in orbital lymphoma treated with primary radiotherapy", Leuk Lymphoma, 56, pp.1266~1270 (2015)[DOI]
- Ferry JA, "Lymphoma of the ocular adnexa: a study of 353 cases", Am J Surg Pathol, 31, pp.170~184 (2007)[DOI]
- Tran KH, "Efficacy of low dose radiotherapy for primary orbital marginal zone lymphoma", Leuk Lymphoma, 54, pp.491~496 (2013)[DOI]
- Bayraktar S, "Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients", Br J Haematol, 152, pp.72~80 (2011)[DOI]
- Ohga S, "Treatment outcome of radiotherapy for localized primary ocular adnexal MALT lymphoma: prognostic effect of the AJCC tumor-node-metastasis clinical staging system", Anticancer Res, 35, pp.3591~3597 (2015)
- Yahalom J, "Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group", Int J Radiat Oncol Biol Phys, 92, pp.11~31 (2015)[DOI]
- Goda JS, "Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy", Cancer, 116, pp.3815~3824 (2010)[DOI]
- Aronow ME, "Ocular adnexal lymphoma: assessment of a tumor-node-metastasis staging system", Ophthalmology, 120, pp.1915~1919 (2013)[DOI]
- Henk JM, "Radiation dose to the lens and cataract formation", Int J Radiat Oncol Biol Phys, 25, pp.815~820 (1993)[DOI]